Red Orbit (Free subscription) | 07/23/2008
By Daniel Connolly Sales rose a slight 2 percent in the second quarter at the Memphis-based consumer products divisions of drug company Schering- Plough Corp.
Business Week (Free subscription) | 07/22/2008
The pharma giants thought their jointly marketed drug could be proved a stronger cholesterol fighter. But a second clinical trial also yields poor results.
Philadelphia Inquirer (Free subscription) | 07/22/2008
European researchers yesterday reported disappointing results for Vytorin, a costly, heavily advertised cholesterol drug, when it came to treating heart-valve disease.
Unfortune (Free subscription) | 07/22/2008
The pharma giants thought their jointly marketed drug could be proved a stronger cholesterol fighter. But a second clinical trial also yields poor results
迷客科技 (Free subscription) | 07/22/2008
Stocks slip on oil, drugs; Apple, Amex drop late Reuters - 9 hours ago NEW YORK ( Reuters ) - Stocks slipped on Monday , as oil turned higher after last week's sharp drop and Merck and Schering - Plough hurt the pharmaceuticals sector.But dismal results after the ... US STOCKS-Stocks slip on oil, drugs; Apple, Amex drop late - Reuters
Forbes (Free subscription) | 07/21/2008
Merck and Schering delay their earnings calls for the release of a study about their controversial cholesterol drug.
The Street (Free subscription) | 07/21/2008
Disappointing news on the cholesterol drug Vytorin is taxing shares of Schering-Plough.
迷客科技 (Free subscription) | 07/21/2008
TI, Apple, Merck, American Express to report MarketWatch - 45 minutes ago LOS ANGELES ( MarketWatch ) - - Late - traders will get a hefty serving of earnings Monday evening with results due from Apple Inc . , Texas Instruments Inc . , Merck & Co . and Schering - Plough ...
Stocks to Watch Today (Free subscription) | 07/21/2008
WCI RALLIES DESPITE DASHING SALE TALK Sometimes you just can’t keep a juicy takeover rumor down. Especially when it’s investors seem to want it so badly. Shares of WCI Communities (WCI), the Carl Ichan-led homebuilder whose exposure to weak housing markets in Florida has cost the company more than 90% of its market value, bounced [...]
MarketBeat (Free subscription) | 07/21/2008
Shares of Schering-Plough Corp. and Merck & Co. were both down after the companies postponed their earnings releases until after today’s close as they await the impending update on a study of whether their Vytorin cholesterol drug reduces heart-attack risk. The press conference discussing the findings is taking place currently in London, led by Terje [...]
Business Spectator (Free subscription) | 07/21/2008
Drug makers' shares fall on the impending trial data. 22 Jul 2008 2:05 AM
The Street (Free subscription) | 07/21/2008
Shares are lower on news both drugmakers are holding off reporting second-quarter results until after the market close.
Examiner (Free subscription) | 07/21/2008
Drug makers Schering-Plough Corp. and Merck & Co. delayed their second-quarter results until after the closing bell Monday so investigators can present data from a study of their cholesterol drug Vytorin.
Star Tribune (Free subscription) | 07/21/2008
TRENTON, N.J. - Drugmakers Schering-Plough Corp. and Merck & Co. took the highly unusual step of delaying their second-quarter results until after the closing bell Monday so European researchers can present data from a study of their cholesterol drug Vytorin.The two companies market Vytorin, which combines Schering-Plough's Zetia and Merck's Zocor, through a joint venture. They had been scheduled to...
Seattle Times (Free subscription) | 07/21/2008
Drug makers Schering-Plough Corp. and Merck & Co. delayed their second-quarter results until after the closing bell Monday so investigators can present data from a study of their cholesterol drug Vytorin.
The last article published by a user on Schering :
sunilnair | 12/24/2007
Bayer Schering Pharma AG: PharmaVitae Profile Introduction This analysis examines the historical and forecast performance for Bayer Schering in the ethical pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually...
